Sequence the genome
We start with the patient's own DNA and read it in full.
Create a gene editing-based therapy for your specific genetic disorder
A more personal approach to rare genetic disease.
Many rare genetic diseases trace back to a single, identifiable change in a person's DNA. Rarivive builds the therapy around that one change.
From one genome to one therapy.
Pinpoint the mutation
We find the causative change behind the disease, the single variant that matters for this person.
Engineer the therapy
We design a gene therapy around that one person's biology, even when no one else shares the variant.
Therapies precisely matched to your biology
Many rare genetic diseases trace back to a single, identifiable change in a person's DNA. But because each variant often affects only a handful of people, no company can justify building a therapy for it. Patients and families are left to manage a condition that could be addressed at its root. Rarivive exists to close that gap by sequencing a patient's genome, pinpointing the causative mutation, and engineering a gene therapy around that one person's biology.
Built around the individual.
Deepak Reyon
Founder & CEO, Rarivive
Deepak Reyon founded Rarivive to build gene-editing therapies for families whose mutation is real, correctable, and unaddressed, one patient at a time. He spent the previous fifteen years advancing genetic medicines from concept into the clinic at Editas, Prime Medicine, and Arena BioWorks.
Get in touch
Let's start
with a conversation.
Have a question or want to learn more about Rarivive? Send us a message and we'll be in touch.
hello@rarivive.com